Basal Cell Skin Cancer, Version 2.2024

Chrysalyne D. Schmults, Rachel Blitzblau, Sumaira Z. Aasi, Murad Alam, Arya Amini, Kristin Bibee, Jeremy Bordeaux, Pei Ling Chen, Carlo M. Contreras, Dominick DiMaio, Jessica M. Donigan, Jeffrey M. Farma, Karthik Ghosh, Kelly Harms, Alan L. Ho, John Nicholas Lukens, Lawrence Mark, Theresa Medina, Kishwer S. Nehal, Paul NghiemKelly Olino, Soo Park, Tejesh Patel, Igor Puzanov, Jason Rich, Aleksandar Sekulic, Ashok R. Shaha, Divya Srivastava, Valencia Thomas, Courtney Tomblinson, Puja Venkat, Yaohui Gloria Xu, Siegrid Yu, Mehran Yusuf, Beth McCullough, Sara Espinosa

Research output: Contribution to journalArticlepeer-review

Abstract

Basal cell carcinoma (BCC) is the most common form of skin cancer in the United States. Due to the high frequency, BCC occurrences are not typically recorded, and annual rates of incidence can only be estimated. Current estimated rates are 2 million Americans affected annually, and this continues to rise. Exposure to radiation, from either sunlight or previous medical therapy, is a key player in BCC development. BCC is not as aggressive as other skin cancers because it is less likely to metastasize. However, surgery and radiation are prevalent treatment options, therefore disfigurement and limitation of function are significant considerations. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline an updated risk stratification and treatment options available for BCC.

Original languageEnglish (US)
Pages (from-to)1181-1203
Number of pages23
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume21
Issue number11
DOIs
StatePublished - 2023

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Basal Cell Skin Cancer, Version 2.2024'. Together they form a unique fingerprint.

Cite this